( en | de | ru )

 

Disambiguation of "Kuhnt, Evelyn"

Author of the publication

copydeleteadd this publication to your clipboard
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era

, , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (14): 2373–2380 (2010)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Jan Kuhnt

Endovaskuläre Stentgrafttherapie der Typ B Aortendissektion: Determinanten des postinterventionellen Überlebens. Uni Duisburg-Essen, (2009)

Sigrid Kuhnt

Irmhild Kuhnt

Gerald Kuhnt

Wolfgang Kuhnt

 

Other publications of authors with the same name

Are renal adverse effects of hydroxyethyl starches merely a consequence of their incorrect use?, , , , , , , and . Wiener klinische Wochenschrift, 123 (5-6): 145–155 (2011)Intensive insulin therapy and pentastarch resuscitation in severe sepsis, , , , , , , , , and 13 other author(s). The New England journal of medicine, 358 (2): 125–139 (2008)Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study, , , , , , , , , and 8 other author(s). The Lancet Oncology, 9 (5): 435–444 (2008)Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial, , , , , , , , , and 19 other author(s). JAMA, 307 (22): 2390–2399 (2012)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, , , , , , , , , and 14 other author(s). The Lancet. Oncology, 7 (5): 379–391 (2006)Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era, , , , , , and . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (14): 2373–2380 (2010)Gene polymorphisms in the heme degradation pathway and outcome of severe human sepsis, , , , , , , , , and 6 other author(s). Shock (Augusta, Ga.), 38 (5): 459–465 (2012)CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group, , , , , , , , , and 11 other author(s). The Lancet Oncology, 12 (11): 1013–1022 (2011)